LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients

• Status: Suspended
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In this trial, various factors that may influence the antibiotic concentrations measured in the sputum of cystic fibrosis patients are studied.

A first factor is aerosol use. As cystic fibrosis patients often use aerosols, such as hypertonic saline, dilution of the antibiotics in sputum can be expected. The extent of this dilution is unknown and will be determined by comparing sputum samples collected before and after the use of an aerosol.

A second factor is the homogeneity of the antibiotics within one sputum sample. Multiple aliquots of the same sputum sample will be compared.

A third factor is the variability between several sputum samples collected during a drainage session. The antibiotic concentrations in 3 separate sputum samples will be compared.

The final goal is to standardise the sputum sample collection and processing of the samples to ensure a accurate concentration measurements in sputum.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Ghent
• Collaborators: Belgische Vereniging voor Strijd tegen Mucoviscidose; King Baudouin Foundation
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Ceftazidime; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam

Criteria

Inclusion Criteria:

• Cystic fibrosis patient

• Sputum production

• Inclusion after receiving at least 3 days of IV therapy with ceftazidime, piperacillin-tazobactam or meropenem

Exclusion Criteria:

• Inability to expectorate sputum